Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4355 - Analysis of BRCA genes and homologous recombination deficiency (HRD) scores in tumours from patients (pts) with metastatic breast cancer (mBC) in the OlympiAD trial

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Breast Cancer

Presenters

Mark Robson

Citation

Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268

Authors

M. Robson1, Z. Lai2, S. Dearden3, J.C. Barrett2, E.A. Harrington3, K. Timms4, J. Lanchbury4, W. Wu5, A. Allen5, C. Goessl5, E. Senkus6, S. Domchek7, D. Hodgson2

Author affiliations

  • 1 ,, Memorial Sloan-Kettering Cancer Center, , - New York/US
  • 2 ,, AstraZeneca, Boston/US
  • 3 ,, AstraZeneca, Cambridge/GB
  • 4 ,, Myriad Genetics, Salt Lake City/US
  • 5 ,, AstraZeneca, Gaithersburg/US
  • 6 ,, Medical University of Gdańsk, Gdansk/PL
  • 7 ,, Basser Center, University of Pennsylvania, Philadelphia/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4355

Background

We conducted tumour testing in pts with germline mutations in BRCA1 and/or BRCA2 (gBRCAm) and HER2-negative mBC in the OlympiAD study (NCT02000622).

Methods

Tumour tissue of gBRCAm pts was analysed with Myriad myChoice HRD Plus, including determination of tumor (t) BRCAm, HRD score and gene-specific loss of heterozygosity (LOH).

Results

Tissue was available from 161/302 pts: tBRCAm status n = 143 (47%); HRD score n = 129 (43%); LOH n = 125 (41%). Concordance of gBRCAm and tBRCAm was 99% (141/142). Absence of LOH was observed in 7/125 pts (6%): 4/49 (8%) BRCA2m, 3/76 (4%) BRCA1m; 2 had a 2nd mutation event (Table). Low HRD scores (<42) were seen in 16% of pts (21/129), with higher rates in BRCA2m vs BRCA1m pts (14/51 [27%] vs 7/78 [9%]) and hormone receptor positive (HR+) vs triple negative (TN; 13/59 [22%] vs 8/70 [11%]). In olaparib (ola) pts with a BRCAm, ORR was 60% (6/10) and 57% (37/65) in pts with HRD score <42 and ≥42, respectively. Hazard ratio for PFS favoured ola vs treatment of physician’s choice (TPC) when HRD score was <42 or ≥ 42.Table: 1936P

Pts with absence of LOH

TreatmentBiopsyGeneVariantHRD scoreHormone receptor status2nd eventRECIST responsePFS (months)
OlaPriBRCA2c.9097dupA (p.Thr3033Asnfs*11)31HR + PR11.0
OlaPriBRCA2c.5946del (p.Ser1982Argfs*22)28HR + PD1.3§
OlaMetBRCA2c.658_659del (p.Val220Ilefs*4)12HR + SD8.2§
OlaPriBRCA2c.7977-1G>C34HR + CR11.0
OlaMetBRCA1c.188T>A (p.Leu63*)56HR + S1580fs*2PR6.5§
TPCMetBRCA1c.5266dupC (p.Gln1756Profs*74)73HR + 494dupT and 528_535delins25PR5.9§
TPCPriBRCA1c.1931del (p.Cys644Phefs*7)41TNSD8.1§

Overall median PFS was 7.0 months for ola vs 4.2 months for TPC;

Censor;

§Event;

Diagnosis to sample interval was ≥7 years. CR, complete response; Met, metastatic; PD, progressive disease; PR, partial response; Pri, primary; SD, stable disease

Conclusions

Tumour testing detected almost all gBRCAm in the study. In this mBC population, absence of LOH was uncommon, indicating a high rate of biallelic inactivation. There was no evidence for a reduction in ola efficacy in the small number of pts with BRCAm HER2-negative mBC whose tumors lack LOH and/or have HRD score <42.

Clinical trial identification

NCT02000622.

Editorial acknowledgement

Medical writing assistance was provided by Debbi Gorman, PhD, from Mudskipper Business, Ltd, funded by AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A. (MSD).

Legal entity responsible for the study

AstraZeneca.

Funding

This study was sponsored by AstraZeneca and is part of an alliance between AstraZeneca and Merck & Co, Inc.

Disclosure

M. Robson: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Uncompensated: Daiichi-Sankyo; Advisory / Consultancy: McKesson; Advisory / Consultancy, Uncompensated: Merck; Advisory / Consultancy, Research grant / Funding (institution), Consulting/advisory: Uncompensated; other transfer of value (editorial services): Pfizer; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Invitae; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Myriad; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution), Funded in part: Grant P30 CA008748: NIH/NCI Cancer Center Support. Z. Lai: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. S. Dearden: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. J.C. Barrett: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. E.A. Harrington: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. K. Timms: Shareholder / Stockholder / Stock options, Full / Part-time employment: Myriad. J. Lanchbury: Shareholder / Stockholder / Stock options, Full / Part-time employment: Myriad. W. Wu: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. A. Allen: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. C. Goessl: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. E. Senkus: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self): Clinigen; Honoraria (self), Travel / Accommodation / Expenses: Egis; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Pierre Fabre; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self): Sandoz; Honoraria (self), Research grant / Funding (institution): Samsung; Honoraria (self), Research grant / Funding (institution): Merck; Research grant / Funding (institution): Boehringer. S. Domchek: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Clovis Oncology; Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): PharmaMar. D. Hodgson: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.